Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 188.64 Billion KRW | 16.87% |
| 2022 | 161.41 Billion KRW | 5.85% |
| 2021 | 152.49 Billion KRW | -11.0% |
| 2020 | 171.34 Billion KRW | 16.6% |
| 2019 | 146.95 Billion KRW | 28.37% |
| 2018 | 114.47 Billion KRW | 0.36% |
| 2017 | 114.06 Billion KRW | 17.84% |
| 2016 | 96.79 Billion KRW | 21.18% |
| 2015 | 79.87 Billion KRW | 7.98% |
| 2014 | 73.97 Billion KRW | 1.99% |
| 2013 | 72.52 Billion KRW | 18.83% |
| 2012 | 61.03 Billion KRW | 25.84% |
| 2011 | 48.5 Billion KRW | 21.09% |
| 2010 | 40.05 Billion KRW | 17.21% |
| 2009 | 34.17 Billion KRW | 4.57% |
| 2008 | 32.68 Billion KRW | 37.66% |
| 2007 | 23.74 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 217.37 Billion KRW | 9.25% |
| 2024 Q1 | 198.98 Billion KRW | 5.48% |
| 2023 Q2 | 169.48 Billion KRW | 1.04% |
| 2023 Q3 | 177.7 Billion KRW | 4.85% |
| 2023 Q4 | 188.64 Billion KRW | 6.15% |
| 2023 FY | 188.64 Billion KRW | 16.87% |
| 2023 Q1 | 167.73 Billion KRW | 3.92% |
| 2022 Q4 | 161.41 Billion KRW | 1.52% |
| 2022 Q3 | 158.99 Billion KRW | -2.27% |
| 2022 Q2 | 162.68 Billion KRW | 5.28% |
| 2022 FY | 161.41 Billion KRW | 5.85% |
| 2022 Q1 | 154.52 Billion KRW | 1.33% |
| 2021 Q2 | 168.24 Billion KRW | 4.26% |
| 2021 Q3 | 165.99 Billion KRW | -1.34% |
| 2021 FY | 152.49 Billion KRW | -11.0% |
| 2021 Q1 | 161.37 Billion KRW | -5.82% |
| 2021 Q4 | 152.49 Billion KRW | -8.13% |
| 2020 Q3 | 152.58 Billion KRW | 5.82% |
| 2020 Q4 | 171.34 Billion KRW | 12.3% |
| 2020 Q2 | 144.19 Billion KRW | 2.63% |
| 2020 FY | 171.34 Billion KRW | 16.6% |
| 2020 Q1 | 140.5 Billion KRW | -4.39% |
| 2019 Q3 | 134.04 Billion KRW | 0.9% |
| 2019 Q1 | 126.82 Billion KRW | 10.79% |
| 2019 FY | 146.95 Billion KRW | 28.37% |
| 2019 Q2 | 132.85 Billion KRW | 4.75% |
| 2019 Q4 | 146.95 Billion KRW | 9.63% |
| 2018 Q1 | 105.3 Billion KRW | -7.68% |
| 2018 Q3 | 112.96 Billion KRW | 2.1% |
| 2018 FY | 114.47 Billion KRW | 0.36% |
| 2018 Q4 | 114.47 Billion KRW | 1.33% |
| 2018 Q2 | 110.64 Billion KRW | 5.07% |
| 2017 FY | 114.06 Billion KRW | 17.84% |
| 2017 Q2 | 108.71 Billion KRW | 0.12% |
| 2017 Q4 | 114.06 Billion KRW | 8.38% |
| 2017 Q3 | 105.24 Billion KRW | -3.19% |
| 2017 Q1 | 108.58 Billion KRW | 12.18% |
| 2016 Q1 | 82.59 Billion KRW | 3.41% |
| 2016 Q2 | 83.67 Billion KRW | 1.3% |
| 2016 Q3 | 96.01 Billion KRW | 14.76% |
| 2016 Q4 | 96.79 Billion KRW | 0.8% |
| 2016 FY | 96.79 Billion KRW | 21.18% |
| 2015 Q1 | 79.79 Billion KRW | 7.87% |
| 2015 Q4 | 79.87 Billion KRW | -4.28% |
| 2015 Q3 | 83.44 Billion KRW | -0.55% |
| 2015 FY | 79.87 Billion KRW | 7.98% |
| 2015 Q2 | 83.9 Billion KRW | 5.15% |
| 2014 Q3 | 72.01 Billion KRW | -5.01% |
| 2014 Q2 | 75.8 Billion KRW | 4.01% |
| 2014 FY | 73.97 Billion KRW | 1.99% |
| 2014 Q4 | 73.97 Billion KRW | 2.72% |
| 2014 Q1 | 72.88 Billion KRW | 0.49% |
| 2013 Q4 | 72.52 Billion KRW | 10.38% |
| 2013 Q2 | 69.81 Billion KRW | 3.83% |
| 2013 Q1 | 67.24 Billion KRW | 10.17% |
| 2013 FY | 72.52 Billion KRW | 18.83% |
| 2013 Q3 | 65.7 Billion KRW | -5.89% |
| 2012 Q1 | 51.69 Billion KRW | 0.0% |
| 2012 FY | 61.03 Billion KRW | 25.84% |
| 2012 Q4 | 61.03 Billion KRW | 0.0% |
| 2011 FY | 48.5 Billion KRW | 21.09% |
| 2011 Q3 | 39 Billion KRW | -3.38% |
| 2011 Q2 | 40.36 Billion KRW | -2.64% |
| 2011 Q1 | 41.46 Billion KRW | 3.5% |
| 2010 Q4 | 40.05 Billion KRW | 20.8% |
| 2010 Q3 | 33.15 Billion KRW | 3.87% |
| 2010 FY | 40.05 Billion KRW | 17.21% |
| 2010 Q1 | 32.55 Billion KRW | -4.73% |
| 2010 Q2 | 31.92 Billion KRW | -1.95% |
| 2009 Q1 | 32.67 Billion KRW | -0.03% |
| 2009 FY | 34.17 Billion KRW | 4.57% |
| 2009 Q4 | 34.17 Billion KRW | 5.42% |
| 2009 Q3 | 32.41 Billion KRW | 7.81% |
| 2009 Q2 | 30.06 Billion KRW | -7.96% |
| 2008 Q1 | 25.24 Billion KRW | 6.33% |
| 2008 Q2 | 26.73 Billion KRW | 5.91% |
| 2008 Q3 | 29.39 Billion KRW | 9.93% |
| 2008 Q4 | 32.68 Billion KRW | 11.19% |
| 2008 FY | 32.68 Billion KRW | 37.66% |
| 2007 Q1 | 21.16 Billion KRW | 0.0% |
| 2007 FY | 23.74 Billion KRW | 0.0% |
| 2007 Q3 | 22.79 Billion KRW | 10.41% |
| 2007 Q2 | 20.64 Billion KRW | -2.45% |
| 2007 Q4 | 23.74 Billion KRW | 4.15% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -327.256% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -60.067% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -106.922% |
| HANDOK Inc. | 94.46 Billion KRW | -99.697% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -788.02% |
| Yuhan Corporation | 284.75 Billion KRW | 33.753% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -62.185% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -1060.259% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 34.684% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -482.516% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -205.62% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -868.539% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -522.99% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -290.183% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -327.256% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -503.836% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -436.277% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -291.959% |
| JW Holdings Corporation | 147.58 Billion KRW | -27.816% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -122.92% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 27.842% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -77.812% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -249.836% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -598.73% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -480.236% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -71.856% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -327.256% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 21.902% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -77.812% |
| Yuhan Corporation | 284.75 Billion KRW | 33.753% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | -50.577% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -204.329% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 27.401% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -77.812% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -136.98% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -283.873% |
| CKD Bio Corp. | 69.08 Billion KRW | -173.07% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -79.527% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -166.832% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -248.964% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -249.836% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 3.143% |
| Boryung Corporation | 189.8 Billion KRW | 0.613% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -231.932% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -205.62% |
| JW Lifescience Corporation | 23.39 Billion KRW | -706.214% |